Skip to main content

Clinical Trials Search at Vanderbilt-Ingram Cancer Center

Neuroplasticity-based Cognitive Remediation for Improving Chemotherapy-related Cognitive Impairment in Breast Cancer Patients

This clinical trial tests whether neuroplasticity-based computerized cognitive remediation works in improving certain types of thinking skills that are important for daily life functioning in breast cancer patients with chemotherapy-related cognitive impairment. Cancer and chemotherapy treatment may change the way the brain functions. As a result, patients who receive cancer treatment may experience problems with their attention, learning, and memory that they did not have before. nCCR is a computer-based program designed to improve certain types of thinking skills that are important for daily life functioning. nCCR may help improve thinking and functioning in patients with attention and memory problems related to cancer treatment.
Breast
N/A
Adults
Not Available
Not Available
Vega, Jennifer
Local
Vanderbilt University
08-01-2022
Supportive Care
VICCBRE2203
NCT05283629

Eligibility

35 Years
BOTH
NO
Inclusion Criteria:

Be between 35 and 80 years of age

Have been diagnosed with noninvasive or invasive breast cancer

Have undergone treatment with systemic chemotherapy within the last 1-8 years

Endorse persistent CRCI subjective complaints

Have no active unstable medical condition

Fluent in and able to read English



Exclusion Criteria:

Any active neurologic or untreated/non-remitted psychiatric disease, (e.g. active major depression or another major psychiatric disorder as described in DSM-5)

Clinically significant cognitive impairment identified on cognitive screening

Diagnosis of mild cognitive impairment or dementia

History of significant head trauma followed by persistent neurologic deficits

History of alcohol or substance abuse or dependence within the past 2 years (DSM-5 criteria)

Any significant systemic illness or unstable medical condition which could lead to difficulty complying with the protocol.

Use of any investigational drugs within 30 days or 5 half-lives whichever is longer, prior to screening

Red-green color blindness

Use of certain central nervous system (CNS) active medications (e.g. antidepressants) will be permitted, provided dosing has been stable for at least 3 months

To learn more about any of our clinical
trials, call 1-800-811-8480 or complete
the online Self-Referral Form here: